Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules
| Autor: | Chen-Tso Tseng, Shu-Jen Chen, Shin-Ru Shih, Gholam Hossein Hakimelahi, Kak-Shan Shia, Hsing-Jang Liu |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Picornavirus
Viral protein viruses medicine.medical_treatment medicine.disease_cause Antiviral Agents Article 3C protease Microbiology Capsid Viral life cycle Drug Discovery medicine Protease Inhibitors Pharmacology Protease biology Chemistry enterovirus capsid protein VP1 General Medicine biology.organism_classification Virology Human enterovirus picornavirus rhinovirus Viral replication Molecular targets Molecular Medicine Enterovirus Rhinovirus Protein Binding |
| Zdroj: | Medicinal Research Reviews |
| ISSN: | 1098-1128 0198-6325 |
| DOI: | 10.1002/med.10067 |
| Popis: | The absence of effective vaccines for most viral infections highlights an urgent necessity for the design and development of effective antiviral drugs. Due to the advancement in virology since the late 1980s, several key events in the viral life cycle have been well delineated and a number of molecular targets have been validated, culminating in the emergence of many new antiviral drugs in recent years. Inhibitors against enteroviruses and rhinoviruses, responsible for about half of the human common colds, are currently under active investigation. Agents targeted at either viral protein 1 (VP1), a relatively conserved capsid structure mediating viral adsorption/uncoating process, or 3C protease, which is highly conserved among different serotypes and essential for viral replication, are of great potential to become antipicornavirus drugs. © 2004 Wiley Periodicals, Inc. Med Res Rev, 24, No. 4, 449–474, 2004 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text